

Supplementary Table 1 – Overview of studies evaluating use of cardiac troponins for diagnosis of myocardial infarction in emergency chest pain presentations in CKD

| Study | N | Biomarker | eGFR | Prediction of MI | | |
|---|-----|--------------------------------|----------|------------------|-------------|----------------------|
| | | | | Sensitivity | Specificity | AUC/PVs |
| Ballocca et al. ¹ 2017 | 113 | cTnI at 3.5 hr > 26.0 ng/L | <30 | 64% | 49% | 0.6 |
| | 113 | cTnI at 3.5 hr > 26.0 ng/L | 30–60 | 65% | 45% | 0.57 |
| | 113 | Peak cTnI > 26.0 ng/L | <30 | 65% | 88% | 0.8 |
| | 113 | Peak cTnI > 26.0 ng/L | 30–60 | 79% | 90% | 0.88 |
| | 534 | cTnT at 3.5 hrs > 14.0 ng/L | <30 | 59% | 43% | 0.52 |
| | 534 | cTnT at 3.5 hrs > 14.0 ng/L | 30–60 | 65% | 45% | 0.57 |
| | 534 | Peak cTnT > 14.0 ng/L | <30 | 83% | 52% | 0.74 |
| | 534 | Peak cTnT > 14.0 ng/L | 30–60 | 84% | 54% | 0.74 |
| Chenevier- Gobeaux et al. ² 2013 | 291 | Peak cTnT > 14.0 ng/L | >60 | 90% | 86% | 0.91 |
| | 75 | Peak cTnT > 14.0 ng/L | ≤60 | 100% | 54% | NR |
| | 75 | Peak cTnT > 35.8 ng/L | ≤60 | 94% | 86% | 0.96 |
| Clemons et al. ³ 2021 | 60 | Δ cTnT ≥ 5 ng/L* | ≥60 | 52% | 79% | PPV 73%, NPV 60% |
| | 29 | Δ cTnT < 5 ng/L* | <60 | 74% | 63% | PPV 82%, NPV 50% |
| | 722 | Presenting cTnI > SST | ≥90 | 76% | 95% | PPV 54%, NPV 98% |
| | 421 | cTnI > SST at 9 hrs | ≥90 | 94% | 94% | PPV 57%, NPV 100% |
| | 445 | Presenting cTnI > SST | 60–89 | 62% | 88% | PPV 39%, NPV 95% |
| Gunsolus et al. ⁴ 2018 | 259 | cTnI > SST at 9 hrs | 60–89 | 93% | 87% | PPV 57%, NPV 98% |
| | 229 | Presenting cTnI > SST | 30–59 | 51% | 79% | PPV 34%, NPV 88% |
| | 149 | cTnI > SST at 9 hrs | 30–59 | 97% | 68% | PPV 45%, NPV 99% |
| | 81 | Presenting cTnI > SST | <30 | 94% | 61% | PPV 39%, NPV 98% |
| | 51 | cTnI > SST at 9 hrs | <30 | 100% | 57% | PPV 27%, NPV 100% |
| | 78 | Presenting cTnI > SST | Dialysis | 70% | 40% | PPV 15%, NPV 90% |
| | 42 | cTnI > SST at 9 hrs | Dialysis | 90% | 41% | PPV 32%, NPV 93% |

| | | | | | | |
|---|-------|----------------------------------|-------|------|------|----------------------|
| Kraus et al. ⁵ 2018 | 7,692 | Presenting cTnI > 30 ng/L | ≥60 | 88% | 91% | PPV 63%, NPV 98% |
| | 7,692 | Presenting cTnT > 14 ng/L | ≥60 | 85% | 73% | PPV 39%, NPV 96% |
| | 1,861 | Presenting cTnI > 30 ng/L | <60 | 92% | 82% | PPV 64%, NPV 97% |
| | 1,861 | Presenting cTnI > 54 ng/L | <60 | 82% | 90% | PPV 74%, NPV 93% |
| | 1,861 | Presenting cTnT > 14 ng/L | <60 | 94% | 26% | PPV 33%, NPV 92% |
| | 1,861 | Presenting cTnT > 50 ng/L | <60 | 66% | 80% | PPV 57%, NPV 82% |
| | 1,799 | Presenting cTnI > 120 ng/L | >60 | 98% | 97% | PPV 80%, NPV 100% |
| | 1,799 | Presenting cTnI > 600 ng/L | >60 | 98% | 98% | PPV 87%, NPV 100% |
| Limkakeng et al. ⁶ 2021 | 331 | Presenting cTnI > 120 ng/L | 31–60 | 98% | 93% | PPV 74%, NPV 100% |
| | 331 | Presenting cTnI > 600 ng/L | 31–60 | 98% | 97% | PPV 88%, NPV 100% |
| | 65 | Presenting cTnI > 120 ng/L | 15–30 | 100% | 82% | PPV 61%, NPV 100% |
| | 65 | Presenting cTnI > 600 ng/L | 15–30 | 100% | 88% | PPV 70%, NPV 100% |
| | 76 | Presenting cTnI > 120 ng/L | <15 | 94% | 85% | PPV 63%, NPV 98% |
| | 76 | Presenting cTnI > 600 ng/L | <15 | 94% | 93% | PPV 79%, NPV 98% |
| Martin et al. ⁷ 1998 | 56 | Presenting cTnI > 800 ng/L | NR | 94% | 100% | PPV 100%, NPV 94% |
| | 3,822 | Presenting cTnI ≥ 5 ng/L * | ≥60 | 98% | 64% | PPV 27%, NPV 100% |
| Miller-Hodges et al. ⁸ 2017 | 3,822 | Presenting cTnI > SST | ≥60 | 99% | 92% | PPV 62%, NPV 100% |
| | 904 | Presenting cTnI ≥ SST † | <60 | 99% | 23% | PPV 30%, NPV 98% |
| | 904 | Presenting cTnI > SST | <60 | 98% | 71% | PPV 50%, NPV 99% |
| Vasudevan et al. ⁹ 2017 | 343 | Peak cTn > 99th percentile †† | ≥60 | NR | NR | 0.98 |
| | 87 | Peak cTn > 99th percentile †† | <60 | NR | NR | 0.93 |

AUC or predictive values are given according to which are reported by study authors. ACS = acute coronary syndrome. * indicates test for ACS rather than MI per se. † indicates test for composite outcome of MI at index presentation or re-admission with MI within 30 days. †† for this study, multiple troponin assays were used and the authors analysed troponins in multiples of the 99th percentile upper limit of normal for each assay. AUC = area under receiver operator curve. MI = myocardial infarction. NR = not reported. NPV = negative predictive value. PPV = positive predictive value. SST = sex-specific threshold of 16 ng/L in women and 34 ng/L in men. Δ indicates change in troponin value across ≥ 2 tests.

References

1. Ballocca F, D'Ascenzo F, Moretti C, et al. High sensitive troponin levels in patients with chest pain and kidney disease: a multicenter registry – the TROPIC study. *Cardiol J* 2017;24:139–50. <https://doi.org/10.5603/CJ.a2017.0025>; PMID: 28281735.
2. Chenevier-Gobeaux C, Meune C, Freund Y, et al. Influence of age and renal function on high-sensitivity cardiac troponin T diagnostic accuracy for the diagnosis of acute myocardial infarction. *Am J Cardiol* 2013;111:1701–7. <https://doi.org/10.1016/j.amjcard.2013.02.024>; PMID: 23540652.
3. Clemons D, Lee A, Ajmeri S, et al. High-sensitivity troponin for suspected acute coronary syndrome in patients with chronic kidney disease versus patients without chronic kidney disease. *J Clin Med Res* 2021;13:326–33. <https://doi.org/10.14740/jocmr4515>; PMID: 34267840.
4. Gunsolus I, Sandoval Y, Smith SW, et al. Renal dysfunction influences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I. *J Am Soc Nephrol* 2018;29:636–43. <https://doi.org/10.1681/ASN.2017030341>; PMID: 29079658.
5. Kraus D, von Jeinsen B, Tzikas S, et al. Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease. *J Am Heart Assoc* 2018;7:e008032. <https://doi.org/10.1161/JAHA.117.008032>; PMID: 30371308.
6. Limkakeng ATJ, Hertz J, Lerebours R, et al. Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction. *Am J Emerg Med* 2021;46:170–5. <https://doi.org/10.1016/j.ajem.2020.06.072>; PMID: 33071083.
7. Martin GS, Becker BN, Schulman G. Cardiac troponin-I accurately predicts myocardial injury in renal failure. *Nephrol Dial Transplant* 1998;13:1709–12. <https://doi.org/10.1093/ndt/13.7.1709>; PMID: 9681716.
8. Miller-Hodges E, Anand A, Shah ASV, et al. High-sensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. *Circulation* 2018;137:425–35. <https://doi.org/10.1161/CIRCULATIONAHA.117.030320>; PMID: 28978551.
9. Vasudevan A, Singer AJ, DeFilippi C, et al. Renal function and scaled troponin in patients presenting to the emergency department with symptoms of myocardial infarction. *Am J Nephrol* 2017;45:304–9. <https://doi.org/10.1159/000458451>; PMID: 28192777.